Human Complement C3 ELISA Kit | MyBioSource MBS135515 product information

product summary

company name :

MyBioSource

product type :

ELISA/assay

product name :

Human Complement C3 ELISA Kit

catalog :

MBS135515

quantity :

1 Kit

price :

365 USD

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS135515

products type :

ELISA Kit

products full name :

Human Complement C3 ELISA Kit

products short name :

Complement C3

other names :

complement C3; Complement C3; complement C3; prepro-C3; C3a anaphylatoxin; complement component C3; complement component C3a; complement component C3b; acylation-stimulating protein cleavage product; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; complement component 3; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1Cleaved into the following 11 chains:Complement C3 beta chainComplement C3 alpha chainC3a anaphylatoxinAcylation stimulating protein; ASP; Alternative name(s):; C3adesArg

products gene name :

other gene names :

C3; C3; ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; CPAMD1; ASP

uniprot entry name :

CO3_HUMAN

host :

Multiple

sequence length :

1663

specificity :

Pooled normal plasma from mouse, rat, pig, rabbit, sheep, canine, and guinea pig were assayed for cross-reactivity. No significant cross-reactivity was observed.

form :

Complete Kit

storage stability :

Store at 4 degree C. Shelf Life: 12 months from manufacture, see label for expiration date

other info1 :

Samples: Human plasma, serum, urine, milk, saliva and cell culture samples. Sensitivity: The minimum detectable dose (MDD) was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates (range OD450: 0.067-0.075) and calculating the corresponding concentration. The MDD was 0.0117 ng/mL.

other info2 :

Intra-assay Precision: Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision. Inter-assay Precision: Three samples of known concentration were tested in ten independent assays to assess inter-assay precision. Intended Uses: This human complement component 3 antigen assay is intended for the quantitative determination of total complement component 3 antigen in human plasma, serum, urine, milk, saliva and cell culture samples. For research use only.

products categories :

Complement; Human Complement ELISA Kits

products description :

Principle of the Assay: Human C3 will bind to the capture antibody coated on the microtiter plate. After appropriate washing steps, biotin labeled anti-human C3 primary antibody binds to the captured protein. Excess primary antibody is washed away and bound antibody is reacted with peroxidase conjugated streptavidin. Following an additional washing step, TMB substrate is used for color development at 450nm. A standard calibration curve is prepared along with the samples to be measured using dilutions of human C3. Color development is proportional to the concentration of total C3 in the samples. Background: Complement Component 3 (C3), the most abundant serum complement component, is a disulfide-linked 185kDa 1,637 amino acid glycoprotein which supports the classical, alternative, and lectin pathways of complement activation [1]. C3 is proteolytically activated by C3-convertase to the anaphylatoxin C3a and the opsonizing agent C3b [2]. Serum concentrations of C3 are increased during acute and chronic inflammation such as rheumatoid arthritis, and are decreased due to increased consumption or autoimmune disorders such as systemic lupus erythematosus [3].

ncbi gi num :

115298678

ncbi acc num :

NP_000055.2

ncbi gb acc num :

NM_000064.2

uniprot acc num :

P01024

ncbi mol weight :

187,148 Da

ncbi pathways :

Activation Of C3 And C5 Pathway (106412); Adaptive Immune System Pathway (366160); Alternative Complement Activation Pathway (106410); Chagas Disease (American Trypanosomiasis) Pathway (147809); Chagas Disease (American Trypanosomiasis) Pathway (147795); Class A/1 (Rhodopsin-like Receptors) Pathway (106357); Complement Activation, Classical Pathway (198823); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484)

ncbi summary :

Complement component C3 plays a central role in the activation of complement system. Its activation is required for both classical and alternative complement activation pathways. People with C3 deficiency are susceptible to bacterial infection. [provided by RefSeq, Feb 2009]

uniprot summary :

C3: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Defects in C3 are the cause of complement component 3 deficiency (C3D). A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9). ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin- containing structure known as Bruch membrane. Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage. Protein type: Inhibitor; Secreted; Secreted, signal peptide. Chromosomal Location of Human Ortholog: 19p13.3-p13.2. Cellular Component: extracellular space; extracellular region; plasma membrane. Molecular Function: protein binding; endopeptidase inhibitor activity; C5L2 anaphylatoxin chemotactic receptor binding; receptor binding. Biological Process: regulation of immune response; complement activation, alternative pathway; fatty acid metabolic process; signal transduction; complement activation; G-protein coupled receptor protein signaling pathway; positive regulation of angiogenesis; positive regulation of activation of membrane attack complex; positive regulation of type IIa hypersensitivity; positive regulation of G-protein coupled receptor protein signaling pathway; regulation of complement activation; innate immune response; immune response; positive regulation of protein amino acid phosphorylation; inflammatory response; complement activation, classical pathway. Disease: Complement Component 3 Deficiency, Autosomal Recessive; Hemolytic Uremic Syndrome, Atypical, Susceptibility To, 5; Macular Degeneration, Age-related, 9

size1 :

1 Kit

price1 :

365 USD

size2 :

5 Kits

price2 :

1450

more info or order :

MyBioSource product webpage